iBET Hosts Fourth and Final Meeting of ADDovenom Project

A Novel Snakebite Therapy Platform of Unparallel Efficacy, Safety and Affordability

On September 11th, iBET hosted the fourth and final annual meeting of the ADDOvenom project.

iBET researchers welcome colleagues from partner institutions for a meeting featuring several presentations about the progress of each work package, insights from Scientific Advisory Board members (Stefanos Grammatikos, Pierre Lafaye, and Gerard Lambeau), and a tour of iBET’s facilities.

Present at the meeting representing iBET were António Roldão (Head of the Cell-based Vaccines Development Laboratory and Coordinator of Late-Stage R&D Unit), researchers Rute Castro, Raquel Garcia, Salomé Neto, and Mariana Bettencourt, as well as VP for Business Development, Manuel Carrondo.

ADDovenom’s main goal is to develop a novel snakebite therapy of unparalleled efficacy, safety, and affordability against the most prevalent Sub-Saharan snakes. To achieve this, the project leverages an innovative platform consisting of a protein-based nanoscaffold known as ADDomer© – a thermostable synthetic virus-like particle with 60 binding sites that are engineered to neutralize and eliminate venom toxins from the bloodstream.

With the project due to end next year, the meeting also included discussions about the next steps for the ADDovenom team.

ADDovenom is an EU-funded project under the H2020 programme, coordinated by the University of Bristol and including collaboration from partners at iBET, Liverpool School of Tropical MedicineUniversity of Liège, and Aix-Marseille University.

Know more on ADDovenom‘s website.

Related news